Topic:

April 2024

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

https://www.lupuscanada.org/wp-content/uploads/AZD1222_PhIII-US-HLR_RNS.pdf

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Lupus Treatment and Access Across Provinces: Take the Patient Survey

Advocacy & SupportNews & Events
Article
Read

Canada Disability Benefit Regulations Finalized | What It Means for Lupus Patients

Advocacy & SupportNews & Events
Article
Read

Support Lupus Awareness – Step Out for Lupus Walk 2025 Calgary

Advocacy & SupportAwareness & Community
Article
Read